Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (9374)	3/24/1999 11:28:00 PM
From: Bluegreen	Read Replies (1) \| Respond to of 17367

George, the difference is historically kids of all ages and various physical characteristics have succumbed to Meningo. if untreated with Neuprex. Didn't Only one kid in Phase II having Meningo. treated with Neuprex die with certain unusual characteristics? Now how could the DSMB project from Phase II if all kids without unusual characteristics survived?

To: aknahow who wrote (9374)	3/25/1999 1:22:00 AM
From: Slugger	Read Replies (1) \| Respond to of 17367

<<It would not mater how many patients were accrued but only the outcome as measured by mortality.>> Which is interesting because if the DSMB is only focusing on the difference between mortality levels in addition to total mortality then BPI is working as well as or better than expected. If the difference wasn't materializing then the trial would have been stopped for futility or total mortality number would have been hit sooner. The only negative scenario that I can come up with is an unexpectedly low placebo mortality rate. But that case becomes weaker every time the DSMB tells XOMA to continue. Can you think of another scenario that is bad for XOMA?